Equillium, Inc. is a biotechnology company. It develops products for autoimmune and inflammatory disorders. The company's product pipeline consists of EQ001 which is in clinical-stage. Equillium, Inc. is based in CA, United States.
| Revenue (Most Recent Fiscal Year) | $41.10M |
| Net Income (Most Recent Fiscal Year) | $-22.40M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.63 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -41.15% |
| Return on Assets (Trailing 12 Months) | -38.29% |
| Current Ratio (Most Recent Fiscal Quarter) | 23.40 |
| Quick Ratio (Most Recent Fiscal Quarter) | 23.40 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.88 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.04 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.39 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.20 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 63.41M |
| Free Float | 52.10M |
| Market Capitalization | $147.74M |
| Average Volume (Last 20 Days) | 0.50M |
| Beta (Past 60 Months) | 1.82 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 17.84% |
| Percentage Held By Institutions (Latest 13F Reports) | 27.05% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |